Brief: Quantum Genomics Begins Phase III FRESH Trial In Difficult-To-Treat And Resistant Hypertension

Quantum Genomics SA

19/12/2019 17:31

Dec 19 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * QUANTUM GENOMICS INITIATES ITS PIVOTAL PHASE III FRESH
TRIAL IN
DIFFICULT-TO-TREAT AND RESISTANT HYPERTENSION
    * TRIAL IS BEING CONDUCTED IN PARTNERSHIP WITH BIOLAB SANUS
PHARMACEUTICALS, AS ANNOUNCED ON DECEMBER 9, 2019
    * FIRST PATIENT ENROLLMENT IS EXPECTED IN Q1 OF 2020
    * TOP-LINE EFFICACY RESULTS ARE ANTICIPATED IN SECOND HALF
OF
2021.
    * PRIMARY ENDPOINT IS CHANGE FROM BASELINE IN SYSTOLIC
AUTOMATED
OFFICE BLOOD PRESSURE

Source text for Eikon:  ID:nGNX5vCFjc 
Further company coverage:  ALQGC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))